Chrysos Corporation Limited (ASX:C79): FY26 Revenue Growth and PhotonAssay Expansion in Focus

Sonal Goyal

28 September 2026 12:40 AM AEST

Chrysos Corporation Limited (ASX:C79): FY26 Revenue Growth and PhotonAssay Expansion in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue reached A$88.1 million as sample throughput increased across the PhotonAssay network.
EBITDA was A$27.2 million, with the Business recording a net profit after tax of A$1.8 million.
The company processed 11.3 million samples during FY26 and had 46 PhotonAssay units operating globally at year end.
Additional assay charges increased as a share of revenue, alongside continued growth in minimum monthly assay payments.
FY27 guidance points to further revenue and EBITDA growth as contracted units move through the deployment pipeline.

Chrysos Corporation Limited (ASX:C79) develops and commercialises PhotonAssay, an automated ore-assay technology used to measure gold and other elements in mineral samples. The company typically installs systems at partner laboratories and earns recurring minimum monthly assay payments plus additional per-sample charges when volumes exceed contracted thresholds. FY26 showed higher revenue, EBITDA and sample throughput as the installed base expanded and usage of existing units increased.

FY26 Revenue and Earnings

Chrysos Corporation Limited (ASX:C79) reported FY26 revenue of A$88.1 million and EBITDA of A$27.2 million. Net profit after tax was A$1.8 million, marking a move into profitability for the year. The result was supported by higher activity across the PhotonAssay network, with 11.3 million samples processed during FY26. The combination of Volume growth and increased utilisation indicates that deployment of additional units was translating into a broader Recurring Revenue base.

PhotonAssay Deployment and Revenue Mix

At year end, Chrysos Corporation Limited (ASX:C79) had 46 PhotonAssay units operating globally. Seven units were deployed during FY26 and a further six were in the process of being installed. Total contracted units, including agreements signed after year end, stood at 87, leaving a sizeable deployment pipeline. Additional assay charges generated A$25.5 million of revenue, while minimum monthly assay payments contributed A$62.5 million. The shift toward higher usage-linked revenue is relevant because it increases the contribution from activity above minimum contracted volumes.

Cash Position and Funding Capacity

Operating cash flow reached A$17.9 million in FY26. Chrysos Corporation Limited (ASX:C79) also reported A$25.9 million in cash and access to a A$140 million undrawn Debt facility. This funding position supports the continued rollout of contracted PhotonAssay units, which requires Capital for equipment manufacture, installation and commissioning before new sites begin contributing revenue.

FY27 Guidance and Operating Priorities

For FY27, Chrysos Corporation Limited (ASX:C79) guided to revenue of A$108 million to A$118 million and EBITDA of A$35 million to A$42 million. The main operational task is converting contracted units into commissioned, revenue-generating systems while increasing throughput on the existing network. International expansion also remains part of the growth plan, with the company already generating a substantial share of revenue outside Australia.

Risks and Considerations

Chrysos Corporation Limited (ASX:C79) remains exposed to execution risk as new units move through manufacturing, installation and commissioning. Delays can defer the start of recurring revenue from contracted sites. Activity is also linked to Mining and exploration expenditure, particularly in gold, while international expansion introduces currency, operational and market-entry risks. The technology model also requires continued performance and adoption as the company expands into additional regions.

Key Insights

Chrysos Corporation Limited (ASX:C79) entered FY27 with a larger installed base, higher FY26 revenue and EBITDA, and a significant contracted deployment pipeline. The key variables now are the pace at which contracted units become operational, the level of sample throughput across the network and the contribution from additional assay charges. Delivery against FY27 guidance will depend on execution across each of these areas rather than on a single near-term catalyst.

FAQs

Q: What does Chrysos Corporation Limited (ASX:C79) do?

A:It develops and deploys PhotonAssay technology for rapid analysis of gold and other elements in mineral samples.

Q: What revenue did Chrysos Corporation Limited (ASX:C79) report for FY26?

A:FY26 revenue was A$88.1 million.

Q: How many PhotonAssay units were operating at FY26 year end?

A:Chrysos Corporation Limited (ASX:C79) had 46 operating units globally at year end.

Q: What is the FY27 guidance for Chrysos Corporation Limited (ASX:C79)?

A:Management guided to revenue of A$108 million to A$118 million and EBITDA of A$35 million to A$42 million.

Q: What are the main risks for Chrysos Corporation Limited (ASX:C79)?

A:Key risks include deployment delays, mining-cycle exposure, technology execution and the complexity of international expansion.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.